Affinage

BCL2A1

Bcl-2-related protein A1 · UniProt Q16548

Length
175 aa
Mass
20.1 kDa
Annotated
2026-06-09
100 papers in source corpus 39 papers cited in narrative 39 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/9 claims corpus-supported (89%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

BCL2A1/BFL-1 is an anti-apoptotic BCL-2 family protein that functions as a context-dependent survival factor in hematopoietic and malignant cells, blocking the mitochondrial (intrinsic) apoptotic pathway (PMID:7478596, PMID:8752150, PMID:10753914). It inhibits cell death by directly engaging pro-apoptotic effectors and BH3-only proteins: it binds the BAX BH3 domain without forming homodimers or heterodimerizing with BCL-2/BCL-xL (PMID:10753914), and its BH3-binding groove captures BIM, the structural basis of which was defined by crystallography revealing distinct binding-site plasticity relative to MCL-1 (PMID:18812174). Mutagenesis localized anti-apoptotic, oncogene-cooperation, and proliferation-permitting activities to the BH1, BH2, and BH4 domains rather than its own BH3 (PMID:9671389). BFL-1 is anchored to the outer mitochondrial membrane through its amphipathic C-terminal helix α9, which regulates its anti-apoptotic function (PMID:19759007). Its protein level is set by ubiquitin-mediated proteasomal degradation that acts as a tumor-suppressive brake — TRIM28 serves as the mitochondrial E3 ligase, antagonized by TRIM17 and modulated by GSK3 phosphorylation — and ubiquitination-resistant mutants accelerate leukemia/lymphoma formation in vivo (PMID:20185581, PMID:30042493). BFL-1 transcription is induced by a broad array of upstream signals, predominantly through NF-κB (driven by LMP1/CD40, HTLV-1 Tax, TNF-α, CARD11, and MUC1-C), as well as by EBNA2 via CBF1/Notch, the lineage factors WT1, Spi-B, and MITF, and FLT3-ITD/STAT5 signaling (PMID:11039911, PMID:14747545, PMID:16484585, PMID:16873269, PMID:22510878, PMID:22553204, PMID:23447565, PMID:35114569, PMID:37562004). This inducibility makes BFL-1 a recurrent resistance determinant against BH3-mimetics such as ABT-737/venetoclax, where it sequesters BIM displaced from BCL-2 (PMID:19008458, PMID:20197552, PMID:37562004). Paradoxically, BFL-1 also harbors latent pro-death activity: calpain cleavage releases membrane-active C-terminal helices that drive cytochrome c release (helix α5 via BAX/BAK, helix α9 through a BAX/BAK-independent membrane-destabilizing mechanism) (PMID:22745672), and under apoptotic OMM lipid conditions full-length BFL-1 can oligomerize and breach the membrane, a function absent in BCL-xL (PMID:30560933). Uniquely among anti-apoptotic BCL-2 proteins, BFL-1 presents a surface-accessible cysteine (C55) within its BH3-binding groove, enabling selective covalent inhibition by NOXA-derived stapled peptides, designed PUMA variants, and small molecules (PMID:27617850, PMID:29276033, PMID:28594323, PMID:32413285, PMID:38894895).

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 1995 Medium

    Established BCL2A1 as a distinct anti-apoptotic BCL-2 family member, defining the gene's molecular identity and tissue bias.

    Evidence cDNA cloning, sequence analysis, and Northern blot showing BH1/BH2 domains and bone-marrow-preferential expression

    PMID:7478596

    Open questions at the time
    • No functional anti-apoptotic assay in initial report
    • Domain requirements not yet mapped
  2. 1996 Medium

    Demonstrated that BFL-1 has genuine anti-apoptotic and oncogenic activity, moving it from a sequence homolog to a functional survival/transformation factor.

    Evidence Overexpression suppressing p53-induced apoptosis and cooperating with E1A in transformation of primary rodent cells

    PMID:8752150

    Open questions at the time
    • Mechanism of apoptosis suppression unresolved
    • Binding partners not identified
  3. 1998 High

    Mapped the functional architecture of BFL-1, showing the BH1/BH2/BH4 domains (not its own BH3) drive activity and separating proliferation from anti-apoptotic functions.

    Evidence Systematic site-directed mutagenesis with apoptosis and transformation readouts

    PMID:9671389

    Open questions at the time
    • No structural model accompanied the mutagenesis
    • Direct partner engagement by each domain not tested
  4. 2000 High

    Identified BAX as a direct binding partner and confirmed selective heterodimerization, establishing the biochemical mechanism of BFL-1 sequestration.

    Evidence Yeast two-hybrid, reciprocal co-IP, yeast lethality rescue, and molecular modeling of a BCL-xL-like fold

    PMID:10753914

    Open questions at the time
    • Structure of complex not solved
    • Whether other BH3 proteins are bound not addressed
  5. 2000 Medium

    Placed BFL-1 downstream of NF-κB and viral oncoproteins, framing it as an inducible survival node coupling inflammatory/viral signaling to apoptosis resistance.

    Evidence Inducible LMP1 system, TNF-α/NF-κB inhibition, and ectopic-expression rescue in lymphoma and lung cancer cells

    PMID:10864681 PMID:11039911

    Open questions at the time
    • Promoter elements not yet defined
    • Relative contribution vs other anti-apoptotic genes unclear
  6. 2004 High

    Dissected the bfl-1 promoter, identifying a specific NF-κB-like motif essential for transactivation by LMP1, CD40, and p65, mechanistically anchoring its NF-κB regulation.

    Evidence Promoter-reporter deletion/mutation mapping, EMSA, and NF-κB inhibition

    PMID:14747545

    Open questions at the time
    • Other transcription factor inputs not yet characterized
  7. 2007 High

    Identified BFL-1 as a lineage-specific survival factor and direct transcriptional target across hematopoietic contexts (pre-T cells, neutrophils, plasmacytoid DCs).

    Evidence shRNA/siRNA knockdown, ChIP, and caspase/apoptosis assays in pre-TCR, TNF-α-treated neutrophil, and Spi-B-driven DC systems

    PMID:15728238 PMID:17942758 PMID:22510878

    Open questions at the time
    • In vivo requirement in these lineages not established by these studies
    • Concentration-dependent dual TNF-α effects mechanistically complex
  8. 2007 High

    Revealed that BFL-1 contains an intrinsic mitochondria-targeting tail-anchor that can itself induce caspase-dependent death independent of BAX/BAK, foreshadowing latent pro-apoptotic activity.

    Evidence GFP-fusion localization, mutagenesis of ATAP residues 147-175, and caspase assays in Bax/Bak-deficient cells

    PMID:17666431

    Open questions at the time
    • Physiological trigger for ATAP release not yet known
    • Relationship to full-length anti-apoptotic function unclear
  9. 2008 High

    Provided the first crystal structure of BFL-1 (with BIM BH3), defining the structural basis for its BH3-binding multi-specificity.

    Evidence X-ray crystallography of the BFL-1:BIM BH3 complex

    PMID:18812174

    Open questions at the time
    • Apo structure and groove dynamics not yet captured
    • Druggable features not yet exploited
  10. 2009 Medium

    Established that the amphipathic α9 helix anchors endogenous BFL-1 to mitochondria and tunes anti-apoptotic activity, localizing function to the OMM.

    Evidence Subcellular fractionation, confocal imaging, and functional assays in lymphocytes and malignant B cells

    PMID:19759007

    Open questions at the time
    • α9 not strictly required for anti-apoptotic activity — secondary localization mechanisms unresolved
  11. 2010 High

    Defined ubiquitination as a tumor-suppressive regulatory brake on BFL-1, with stabilization accelerating malignancy in vivo.

    Evidence Ubiquitination-resistant mutants in a mouse leukemia/lymphoma model with Lck/IKK/Akt/ERK signaling analysis

    PMID:20185581

    Open questions at the time
    • E3 ligase identity not yet established
    • Phospho-regulation not defined
  12. 2010 Medium

    Mechanistically linked BFL-1 to BH3-mimetic resistance, showing it sequesters BIM displaced from BCL-2 by ABT-737 in lymphoma and the CLL microenvironment.

    Evidence Resistant cell lines, CD154/IL-4 co-culture, BIM co-IP, and shRNA rescue

    PMID:19008458 PMID:20197552

    Open questions at the time
    • Relative weighting vs MCL-1 context-dependent
    • Whether covalent targeting could overcome resistance untested here
  13. 2012 High

    Uncovered a conditional pro-apoptotic conversion of BFL-1, where calpain cleavage liberates membrane-active helices driving cytochrome c release through both BAX/BAK-dependent and -independent routes.

    Evidence In vitro calpain cleavage, isolated-mitochondria permeabilization, domain mutagenesis, and Bax/Bak-deficient controls

    PMID:22745672

    Open questions at the time
    • In vivo relevance of calpain switch not established
    • Trigger for calpain access to BFL-1 unclear
  14. 2013 High

    Identified MITF-driven BCL2A1 amplification as a melanoma-specific oncogenic dependency, extending BFL-1 biology beyond hematopoiesis.

    Evidence ChIP, promoter assays, shRNA/overexpression, and xenograft models in melanoma and melanocytes

    PMID:23447565 PMID:25486183

    Open questions at the time
    • Why MITF restricts high expression to melanoma not fully resolved
  15. 2015 High

    Demonstrated an in vivo physiological requirement for BCL2A1 in mature B-cell homeostasis via a BCR/Syk/Btk-driven A1/BIM survival axis.

    Evidence Conditional knockdown mouse model with flow cytometry and Syk/Btk inhibitor epistasis

    PMID:26450454

    Open questions at the time
    • Knockdown (not full knockout) leaves residual function unresolved
  16. 2018 High

    Identified TRIM28 as the BFL-1 E3 ligase counteracted by TRIM17 and GSK3, completing the post-translational degradation circuit at mitochondria.

    Evidence Reciprocal mitochondrial co-IP, ubiquitination and knockdown assays, GSK3 pharmacology

    PMID:30042493

    Open questions at the time
    • Precise GSK3 phospho-sites and degron not mapped
    • Stoichiometry of TRIM17/TRIM28 competition unclear
  17. 2018 High

    Resolved three membrane-level inhibitory mechanisms and a lipid-triggered pro-death function in which BFL-1 oligomerizes to breach the OMM — a property unique among anti-apoptotic BCL-2 proteins.

    Evidence Liposome reconstitution, quantitative permeabilization assays, oligomerization analysis, and cell-based validation

    PMID:30560933

    Open questions at the time
    • Physiological lipid changes that flip the switch not defined in cells
    • Structural form of the oligomer unknown
  18. 2017 High

    Solved apo and ligand-bound BFL-1 structures revealing a surface-accessible C55 in the BH3-binding groove and defined covalent and computationally designed BH3 ligands as selective BFL-1 inhibitors.

    Evidence Crystallography of apo and covalent complexes, stapled/designed BH3 peptides validated by MS, FP binding, and mitochondrial/cell apoptosis assays

    PMID:27617850 PMID:28026162 PMID:28594323 PMID:29276033

    Open questions at the time
    • Peptide leads not yet drug-like for in vivo use
  19. 2024 High

    Advanced selective BFL-1 inhibition from peptides to small molecules, establishing C55-targeting covalent chemistry as a tractable therapeutic strategy.

    Evidence Disulfide tethering and DNA-encoded library screens with cocrystal structures of covalent C55 adducts and mitochondrial apoptosis assays

    PMID:32413285 PMID:38894895

    Open questions at the time
    • Cellular potency and selectivity in vivo not yet established
    • Pharmacokinetics of covalent ligands undefined
  20. 2023 Medium

    Extended the NF-κB-driven resistance paradigm to defined oncogenic lesions, showing CARD11 gain-of-function and FLT3-ITD/STAT5 drive BCL2A1-mediated venetoclax/therapy resistance that can be reversed pharmacologically.

    Evidence scRNA-seq, MALT1/MUC1-C/STAT5/BET/CDK9 inhibition with in vitro and PDX models

    PMID:29760958 PMID:33259592 PMID:35114569 PMID:37562004

    Open questions at the time
    • Direct vs indirect transcriptional effects of some inhibitors not fully separated
    • Combination strategies not clinically validated

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the anti-apoptotic versus pro-death balance of BFL-1 is governed in living cells — the in vivo triggers for calpain cleavage and lipid-induced oligomerization — and whether covalent C55 inhibitors achieve durable efficacy in vivo remain open.
  • No in vivo demonstration of the lipid/calpain pro-death switch
  • Small-molecule BFL-1 inhibitors not yet validated in animal disease models

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008289 lipid binding 3 GO:0098772 molecular function regulator activity 3 GO:0140313 molecular sequestering activity 3
Localization
GO:0005739 mitochondrion 4
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-5357801 Programmed Cell Death 4 R-HSA-1643685 Disease 3
Partners
BAXBIMGSK3NOXATRIM17TRIM28

Evidence

Reading pass · 39 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1995 BFL-1 (BCL2A1) was identified as a novel BCL-2 family member with 72% amino acid identity to murine A1, containing conserved BH1 and BH2 domains, and preferentially expressed in bone marrow. cDNA cloning, sequence analysis, Northern blot Oncogene Medium 7478596
1996 BFL-1 suppresses p53-induced apoptosis and cooperates with E1A oncogene in transformation of primary rodent epithelial cells, demonstrating anti-apoptotic and oncogenic activities. Overexpression in cell lines, apoptosis assay, transformation assay Cancer research Medium 8752150
1998 Mutational analysis of BFL-1 showed that BH1, BH2, and BH4 domains are required for anti-apoptotic, oncogene cooperation, and proliferation-facilitating activities, while BH3 mutation does not affect function. C-terminal 24 amino acid deletion partially reduces all activities. Gln residues in the N-terminal/BH4 region are essential for the proliferation-permitting activity. Site-directed mutagenesis, overexpression, apoptosis assays, transformation assays Oncogene High 9671389
2000 BFL-1 interacts with BAX (but not BCL-2 or BCL-xL) via the BAX BH3 domain, as shown in yeast two-hybrid and co-immunoprecipitation. BFL-1 does not form homodimers. Overexpression confers resistance to apoptosis from serum deprivation in REF52 cells, and neutralizes BAX lethality in yeast. Molecular modeling suggests BFL-1 has a 7-alpha-helix core structure similar to BCL-xL. Yeast two-hybrid, co-immunoprecipitation, yeast lethality assay, molecular modeling, overexpression The Journal of biological chemistry High 10753914
2000 EBV latent membrane protein LMP1 transcriptionally upregulates bfl-1 mRNA in Burkitt's lymphoma cells, partly through increased mRNA stability. Ectopic BFL-1 expression protects against apoptosis from growth factor deprivation in EBV-positive cells. Inducible LMP1 expression system, Northern blot, ectopic overexpression, apoptosis assay Journal of virology Medium 10864681
2000 TNF-alpha and chemotherapeutic agents upregulate BCL-xL and BFL-1/A1 expression via an NF-κB-dependent pathway in A549 lung cancer cells. Ectopic expression of BFL-1/A1 at physiological levels provides differential protection against TNF-alpha and chemotherapy in NF-κB-deficient cells. NF-κB inhibition, ectopic overexpression, cytotoxicity assays Oncogene Medium 11039911
2003 BCL2A1 encodes two HLA-restricted minor histocompatibility antigens (mHAgs) derived from SNP-encoded peptides, presented by HLA-A*2402 and HLA-B*4403 on hematopoietic lineage cells exclusively, identified by CTL clone lytic patterns and minigene transfection/epitope reconstitution assays. CTL clone lysis assays, minigene transfection, synthetic peptide epitope reconstitution, two-point linkage analysis The Journal of experimental medicine High 12771180
2003 A novel splice variant, Bfl-1S, contains four BH domains and a KKRK nuclear localization sequence at its C-terminus, which directs nuclear localization (demonstrated by GFP fusion confocal microscopy). Bfl-1S has anti-apoptotic function against Bax and staurosporine, inhibiting cleavage of Bid and caspases 3 and 8. RT-PCR, GFP fusion confocal microscopy, co-expression with Bax, caspase activity assays Oncogene Medium 12717423
2004 LMP1 drives bfl-1 promoter activity via NF-κB-dependent mechanism involving TNFR-associated factor 2 recruitment, primarily through CTAR2 domain. A 95-bp promoter region with a novel NF-κB-like binding motif is essential for transactivation by LMP1, CD40, and NF-κB p65. CD40 activation similarly increases bfl-1 mRNA via NF-κB. Promoter-reporter assays, NF-κB inhibition, EMSA, deletion/mutation analysis of promoter Journal of virology High 14747545
2005 Pre-TCR signaling induces BCL2A1 expression to promote pre-T cell survival by inhibiting caspase-3 activation. Knockdown of BCL2A1 compromises survival even in the presence of functional pre-TCR signaling. shRNA knockdown, caspase-3 activity assay, pre-TCR signaling pathway analysis The Journal of experimental medicine Medium 15728238
2005 BCL2A1 is upregulated by Anaplasma phagocytophilum infection in neutrophils through transcriptional upregulation (blocked by actinomycin D), maintaining mitochondrial membrane potential and preventing caspase-3 activation to inhibit apoptosis. mRNA quantification, actinomycin D block, mitochondrial membrane potential dyes (Mitotracker/JC-1), caspase-3 activity assay Cellular microbiology Medium 15617521
2006 BCL2A1 is a direct transcriptional target of WT1 (-Ex5/-KTS) isoform: promoter-reporter assays and chromatin immunoprecipitation showed direct WT1 binding and activation of the A1/BFL1 promoter. Constitutive A1 expression induces spontaneous granulocytic differentiation and resistance to apoptosis and chemotherapy in 32D cl3 myeloblasts. cDNA array, RT-PCR, promoter-reporter assay, chromatin immunoprecipitation, constitutive expression Blood High 16484585
2006 EBNA2 upregulates bfl-1 transcription through a CBF1/RBP-Jκ-dependent pathway (a Notch signaling component), requiring a core CBF1-binding site on the bfl-1 promoter, and acting independently of NF-κB. Loss of both EBNA2 and LMP1 together is required to significantly reduce bfl-1 expression. Promoter-reporter assays, CBF1 mutant analysis, EBV protein deletion, luciferase assay Journal of virology Medium 16873269
2006 ALK-positive ALCL cells require BCL2A1 expression for survival and growth; BCL2A1 is a transcriptional target of ALK signaling. Functional RNAi knockdown of BCL2A1 in ALK-positive ALCL cells suppresses transformation and survival. Gene expression profiling, inducible RNAi, ALK inhibitors, functional RNAi screen The Journal of clinical investigation Medium 17111047
2007 TNF-alpha induces BFL-1 expression in neutrophils at low concentrations (≤1 ng/mL) while at high concentrations (≥10 ng/mL) it triggers caspase-dependent Mcl-1 degradation. These opposing effects on two separate anti-apoptotic systems explain TNF-alpha's dual effects on neutrophil apoptosis. Western blot, flow cytometry, caspase inhibition, mRNA analysis Blood Medium 17942758
2007 Spi-B transcription factor directly induces BCL2-A1 expression to control survival of plasmacytoid dendritic cells and their progenitors during differentiation from hematopoietic precursors. ChIP, promoter assay, siRNA knockdown, flow cytometry apoptosis assay, differentiation assay Blood High 22510878
2007 The amphipathic tail-anchoring peptide (ATAP; residues 147-175) of Bfl-1 targets specifically to mitochondria and induces caspase-dependent apoptosis independent of Bax or Bak. Lysine residues flanking ATAP are required for mitochondrial targeting; charged residues contributing to amphipathic character are critical for pro-apoptotic function. GFP-fusion subcellular localization, mutagenesis, caspase assay, Bax/Bak-deficient cells Journal of cell science High 17666431
2008 Crystal structure of BFL-1 in complex with a BIM BH3 peptide reveals distinct features at the peptide-binding site with local plasticity of hydrophobic interactions compared to MCL-1:BIM, suggesting the structural basis for multi-specificity of BIM binding to anti-apoptotic proteins. X-ray crystallography FEBS letters High 18812174
2008 De novo synthesis of BCL2A1 (and BCL-xL) mediates ~1000-fold resistance to ABT-737 in CLL cells cultured on CD154-expressing fibroblasts with IL-4 (mimicking lymph node microenvironment), acting upstream of mitochondrial perturbation. BCL2A1 is responsible for resistance at high ABT-737 concentrations. Co-culture model, western blot, protein synthesis inhibition, flow cytometry apoptosis assay Blood Medium 19008458
2009 The C-terminal helix α9 of Bfl-1 is amphipathic and required for mitochondrial membrane anchoring; endogenous Bfl-1 is tightly associated with mitochondria by its C-terminus in both healthy and apoptotic lymphocytes and malignant B cells. The amphipathic character of α9 regulates the anti-apoptotic function of Bfl-1, though it is not absolutely required for anti-apoptotic activity. Subcellular fractionation, confocal microscopy, molecular modeling, functional anti-apoptotic assays The Journal of biological chemistry Medium 19759007
2010 Ubiquitination is a critical tumor suppressor mechanism for Bfl-1; ubiquitination-resistant mutants show increased protein stability and greatly accelerated tumor formation in a mouse leukemia/lymphoma model. Tyrosine kinase Lck is upregulated in these tumors and activates IκB kinase, Akt, and ERK signaling. Ubiquitination-resistant mutants, mouse leukemia/lymphoma model, shRNA knockdown, western blot Blood High 20185581
2010 Acquired resistance to ABT-737 in lymphoma cells is mediated by increased BFL-1 and/or MCL-1 proteins, which sequester pro-apoptotic BIM after it is displaced from BCL-2 by ABT-737. MCL-1 and BFL-1 upregulation occurs at the transcript level and is also dynamically induced within hours of ABT-737 treatment. Derived resistant cell lines, western blot, shRNA, BIM co-immunoprecipitation, flavopiridol treatment Blood Medium 20197552
2012 µ-Calpain cleavage of full-length Bfl-1 releases C-terminal membrane-active α-helices, converting Bfl-1 from anti-apoptotic to pro-apoptotic. Helix α5 of Bfl-1 induces cell death and cytochrome c release through a Bax/Bak-dependent mechanism; helix α9 promotes cytochrome c release through a unique membrane-destabilizing action independent of Bax/Bak. In vitro calpain cleavage, isolated mitochondria permeabilization, Bax/Bak-deficient cells, cytochrome c release assay PloS one High 22745672
2012 HTLV-1 Tax protein induces bfl-1 transcription through the canonical NF-κB pathway, and cooperates with c-Jun or JunD (but not JunB) AP-1 transcription factors via NF-κB and AP-1 binding sites in the bfl-1 promoter. HBZ inhibits c-Jun-induced but increases JunD-induced bfl-1 activation. Both Bfl-1 and Bcl-xL (not Bcl-2) are required for HTLV-1-infected T-cell survival. Promoter-reporter assays, ChIP, siRNA knockdown, apoptosis assays The Journal of biological chemistry High 22553204
2013 BCL2A1 is a direct transcriptional target of the melanoma oncogene MITF, which restricts high-level BCL2A1 expression to melanoma. BCL2A1 is recurrently amplified in ~30% of melanomas and is necessary for melanoma growth; BCL2A1 overexpression promotes melanomagenesis in BRAF-immortalized melanocytes. ChIP, promoter assays, shRNA knockdown, overexpression in melanocytes, in vivo xenograft Proceedings of the National Academy of Sciences of the United States of America High 23447565
2014 Bfl-1 is mitochondrially resident in both resting and apoptotic melanocytes and is regulated by proteasome and NF-κB pathways. siRNA-mediated knockdown enhances sensitivity to drug treatments; forced Bfl-1 overexpression is protective against chemotherapy-induced apoptosis. Subcellular fractionation, siRNA knockdown, proteasome inhibition, NF-κB inhibition, overexpression, apoptosis assay The international journal of biochemistry & cell biology Medium 25486183
2015 Conditional knockdown of BCL2A1/A1 in mice defines a critical role in mature B-cell homeostasis, and identifies the A1/Bim axis as a target of BCR-dependent survival signals mediated by Syk and Btk kinases. Conditional knockdown mouse model (rtTA-driven), flow cytometry, genetic epistasis with Syk/Btk inhibitors Cell death and differentiation High 26450454
2016 BFL-1 contains a unique surface-accessible cysteine (C55) within its BH3-binding groove. Stapled BH3 peptides bearing acrylamide warheads derived from NOXA BH3 form irreversible covalent bonds with C55 of BFL-1, selectively inhibiting BFL-1 and reactivating apoptosis. A natural juxtaposition of cysteines at the NOXA BH3/BFL-1 interface enables this selectivity. Covalent stapled peptide synthesis, mass spectrometry, in vitro binding assay, cell-based apoptosis assay Cell chemical biology High 27617850
2016 Human NOXA binds human BFL-1 potently and covalently via conserved Cys residues, with over 100-fold increased affinity over human MCL-1, suggesting that the selectivity of BH3 interactions differs between mouse and human sequences and that BFL-1 is the primary cellular target of NOXA in humans. Binding affinity measurements, mass spectrometry for covalent interaction, BH3 profiling ACS chemical biology Medium 28026162
2017 Crystal structure of apo BFL-1 at 1.69-Å resolution reveals a surface-accessible C55 within the BH3-binding groove, unique among BCL-2 proteins. Crystal structure of BFL-1 in complex with a covalent stapled NOXA BH3 peptide shows sulfhydryl bond formation and a newly formed hydrophobic cavity with conformational change upon BH3 ligand binding. X-ray crystallography (apo and complex structures) Structure High 29276033
2017 Computationally designed PUMA BH3 variants bearing epistatic mutations bind BFL-1 in a shifted geometry (revealed by crystal structure) with >150-fold selectivity for BFL-1 over other BCL-2 paralogs, potently trigger mitochondrial outer membrane permeabilization in BFL-1-dependent cells, and an electrophile-modified variant reacts with cysteine near the peptide-binding groove to augment specificity. Computational design, crystal structure, fluorescence polarization binding assay, mitochondrial permeabilization assay, cell-based selectivity assay eLife High 28594323
2018 TRIM28 is an E3 ubiquitin ligase for BCL2A1; endogenous TRIM28 and BCL2A1 bind each other at mitochondria and TRIM28 knockdown decreases BCL2A1 ubiquitination. TRIM17 stabilizes BCL2A1 by blocking TRIM28 from binding and ubiquitinating BCL2A1. GSK3 is involved in phosphorylation-mediated inhibition of BCL2A1 degradation. Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, subcellular fractionation, western blot Cell death and differentiation High 30042493
2018 MUC1-C activates the BCL2A1 gene via an NF-κB p65-mediated mechanism in TNBC cells, linking MUC1-C/NF-κB signaling to BCL2A1 induction and EMT. Genetic and pharmacologic targeting of MUC1-C suppresses BCL2A1 expression. shRNA and pharmacologic targeting of MUC1-C, NF-κB p65 ChIP/reporter assays, western blot Signal transduction and targeted therapy Medium 29760958
2018 BFL1 inhibits apoptosis through three distinct membrane-level mechanisms (differing from BCLXL). Critically, changes in OMM lipid composition during apoptosis activate a pro-death function of BFL1 via noncanonical oligomerization and breaching of the outer mitochondrial membrane permeability barrier — a function absent in BCLXL and distinct from BAX. Synthetic membrane models (liposomes), quantitative permeabilization assays, cell-based assays, protein oligomerization analysis Cell death and differentiation High 30560933
2020 Disulfide tethering screen identified that C55 of BFL-1 in its BH3-binding groove can be targeted by small molecules; an N-acetyltryptophan analog (304 Da adduct) covalently targets C55, blocks BH3-binding functionality, and reverses BFL-1-mediated suppression of mitochondrial apoptosis. Structural analysis implicated the conserved leucine-binding pocket with conformational remodeling. Disulfide tethering screen, X-ray crystallography of covalent complex, mitochondrial apoptosis assay Cell chemical biology High 32413285
2021 CDK9 inhibitors rapidly downregulate both BFL-1 and MCL-1 at the transcriptional level, inducing apoptosis in BH3-mimetic-resistant lymphoma cell lines in vitro and driving tumor regressions in vivo in DLBCL patient-derived xenograft models expressing Bfl-1. CDK9 inhibitor treatment, western blot, in vitro apoptosis assay, PDX in vivo model Blood Medium 33259592
2022 BCL2A1 transcription is regulated by STAT5 downstream of FLT3-ITD signaling; gilteritinib (type I TKI) inhibits BCL2A1 expression through STAT5 inactivation. BCL2A1 promoter contains a BRD4 binding site; BET inhibitor CPI-0610 downregulates BCL2A1 in FLT3-mutated AML cells. CAGE technology, western blot, overexpression, STAT5 inhibition, BET inhibitor treatment Translational oncology Medium 35114569
2023 CARD11 gain-of-function mutations directly increase transcription of BCL2A1 via NF-κB1 pathway in mantle cell lymphoma, leading to venetoclax resistance. MALT1 protease inhibition reduces BCL2A1 expression by blocking CARD11-dependent NF-κB1 transduction. Single-cell RNA-seq, genomic analysis, functional overexpression, MALT1 inhibitor treatment, in vitro and in vivo models Blood Medium 37562004
2024 A DNA-encoded chemical library screen identified the first reversible covalent small-molecule ligand for BFL-1 binding through Cys55 (cyano-acrylamide mechanism). Cocrystal structure confirmed Cys55 covalent binding mode in the BFL-1 BH3-binding groove. DEL screen, biophysical assays, X-ray crystallography of covalent complex, SAR exploration ACS medicinal chemistry letters High 38894895

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 312 20197552
2008 Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 292 19008458
2002 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. Journal of immunology (Baltimore, Md. : 1950) 285 12391199
2011 BCL2A1: the underdog in the BCL2 family. Cell death and differentiation 255 22075983
2013 BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proceedings of the National Academy of Sciences of the United States of America 191 23447565
1996 Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 159 8895507
1995 A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 133 7478596
2006 Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. The Journal of clinical investigation 132 17111047
2003 Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. The Journal of experimental medicine 118 12771180
2012 Evaluation of a DNA microarray for the rapid detection of extended-spectrum β-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). The Journal of antimicrobial chemotherapy 114 22604450
2009 ACC (1-aminocyclopropane-1-carboxylate) deaminase activity, a widespread trait in Burkholderia species, and its growth-promoting effect on tomato plants. Applied and environmental microbiology 108 19700546
2005 The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival. The Journal of experimental medicine 98 15728238
1996 bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. Cancer research 97 8752150
1999 A novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia. Antimicrobial agents and chemotherapy 95 10428914
2000 Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene 91 11039911
2007 The dual effects of TNFalpha on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1. Blood 80 17942758
2012 Single-copy gene fluorescence in situ hybridization and genome analysis: Acc-2 loci mark evolutionary chromosomal rearrangements in wheat. Chromosoma 77 23052335
2009 The chemoreceptor genes of the waterflea Daphnia pulex: many Grs but no Ors. BMC evolutionary biology 77 19383158
2007 GRSDB2 and GRS_UTRdb: databases of quadruplex forming G-rich sequences in pre-mRNAs and mRNAs. Nucleic acids research 77 18045785
2012 Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell death & disease 74 22875003
2000 Outbreak of Klebsiella pneumoniae producing transferable AmpC-type beta-lactamase (ACC-1) originating from Hafnia alvei. FEMS microbiology letters 73 10828397
2000 The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line. Journal of virology 70 10864681
2005 Anaplasma phagocytophilum inhibits human neutrophil apoptosis via upregulation of bfl-1, maintenance of mitochondrial membrane potential and prevention of caspase 3 activation. Cellular microbiology 68 15617521
2016 Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors. Cell chemical biology 65 27617850
1996 Antitumor agents. 163. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethylepipodophyllotoxin analogs using the modified CoMFA/q2-GRS approach. Journal of medicinal chemistry 65 8691468
2005 High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. International journal of cancer 64 15499630
2008 Completing the family portrait of the anti-apoptotic Bcl-2 proteins: crystal structure of human Bfl-1 in complex with Bim. FEBS letters 63 18812174
2000 Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells. The Journal of biological chemistry 63 10753914
1998 Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities. Oncogene 59 9671389
1997 Behavioral and neuroendocrine responses controlled by the concerted action of central mineralocorticoid (MRS) and glucocorticoid receptors (GRS). Psychoneuroendocrinology 55 9264153
2018 Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer. Signal transduction and targeted therapy 51 29760958
2018 TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1. Cell death and differentiation 50 30042493
2012 Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer research 50 22865454
2007 Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia. British journal of cancer 50 17726463
2018 Bicyclic Helical Peptides as Dual Inhibitors Selective for Bcl2A1 and Mcl-1 Proteins. Journal of medicinal chemistry 49 29584430
2000 Biochemical-genetic characterization and regulation of expression of an ACC-1-like chromosome-borne cephalosporinase from Hafnia alvei. Antimicrobial agents and chemotherapy 49 10817695
2004 Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. Journal of virology 48 14747545
2005 Retinoid x receptor agonists increase bcl2a1 expression and decrease apoptosis of naive T lymphocytes. Journal of immunology (Baltimore, Md. : 1950) 45 16339527
2006 The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood 42 16484585
2017 Crystal Structures of Anti-apoptotic BFL-1 and Its Complex with a Covalent Stapled Peptide Inhibitor. Structure (London, England : 1993) 40 29276033
2005 In vivo transfer of plasmid-encoded ACC-1 AmpC from Klebsiella pneumoniae to Escherichia coli in an infant and selection of impermeability to imipenem in K. pneumoniae. Antimicrobial agents and chemotherapy 40 16048985
2005 Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction. Oncogene 39 15592513
1995 Characterization of a new family of tobacco highly repetitive DNA, GRS, specific for the Nicotiana tomentosiformis genomic component. Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology 38 7606363
2014 Role of the pro-survival molecule Bfl-1 in melanoma. The international journal of biochemistry & cell biology 37 25486183
1997 Expression of a novel Bcl-2 related gene, Bfl-1, in various human cancers and cancer cell lines. Anticancer research 37 9494579
2012 Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells. The Journal of biological chemistry 36 22553204
2017 Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. eLife 35 28594323
2016 hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents. ACS chemical biology 34 28026162
2012 FGF-2 inhibits TNF-α mediated apoptosis through upregulation of Bcl2-A1 and Bcl-xL in ATDC5 cells. BMB reports 34 22617452
2013 Peptide ligands for pro-survival protein Bfl-1 from computationally guided library screening. ACS chemical biology 33 23363053
2012 The transcription factor Spi-B regulates human plasmacytoid dendritic cell survival through direct induction of the antiapoptotic gene BCL2-A1. Blood 33 22510878
2020 Identification of a Covalent Molecular Inhibitor of Anti-apoptotic BFL-1 by Disulfide Tethering. Cell chemical biology 32 32413285
2014 MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2. Oncology letters 32 25621074
2003 Bfl-1S, a novel alternative splice variant of Bfl-1, localizes in the nucleus via its C-terminus and prevents cell death. Oncogene 32 12717423
2014 Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression. Endocrine-related cancer 30 25012986
2020 Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins. Journal of medicinal chemistry 29 31971799
2006 IgE-receptor activation induces survival and Bfl-1 expression in human mast cells but not basophils. Allergy 29 16918505
2002 Purification and characterization of maltooligosaccharide-forming amylase from Bacillus circulans GRS 313. Journal of industrial microbiology & biotechnology 29 11986918
2021 Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy. European journal of medicinal chemistry 28 34034128
2019 Disruption and Overexpression of the Gene Encoding ACC (1-Aminocyclopropane-1-Carboxylic Acid) Deaminase in Soil-Borne Fungal Pathogen Verticillium dahliae Revealed the Role of ACC as a Potential Regulator of Virulence and Plant Defense. Molecular plant-microbe interactions : MPMI 27 30520678
2015 The miR-573/apoM/Bcl2A1-dependent signal transduction pathway is essential for hepatocyte apoptosis and hepatocarcinogenesis. Apoptosis : an international journal on programmed cell death 27 26201458
2002 [Identification of plasmid-encoded cephalosporinase ACC-1 among various enterobacteria (Klebsiella pneumoniae, Proteus mirabilis, Salmonella) isolated from a Tunisian hospital (Sfax 997-2000)]. Pathologie-biologie 27 11873633
1997 GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes. Oncogene 27 9050999
2019 Tertiary Structural Motif Sequence Statistics Enable Facile Prediction and Design of Peptides that Bind Anti-apoptotic Bfl-1 and Mcl-1. Structure (London, England : 1993) 26 30773399
2012 Suppressors of cytokine signaling promote Fas-induced apoptosis through downregulation of NF-κB and mitochondrial Bfl-1 in leukemic T cells. Journal of immunology (Baltimore, Md. : 1950) 26 23152563
2004 Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant. British journal of haematology 26 14871250
2011 The respective and interaction effects of spinal GRs and MRs on radicular pain induced by chronic compression of the dorsal root ganglion in the rat. Brain research 25 21550593
2007 The tail-anchoring domain of Bfl1 and HCCS1 targets mitochondrial membrane permeability to induce apoptosis. Journal of cell science 25 17666431
2021 Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Blood 24 33259592
2019 MiR-140-5p inhibits cell proliferation and metastasis by regulating MUC1 via BCL2A1/MAPK pathway in triple negative breast cancer. Cell cycle (Georgetown, Tex.) 24 31411515
2010 Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. Blood 24 20185581
2009 C-terminal residues regulate localization and function of the antiapoptotic protein Bfl-1. The Journal of biological chemistry 23 19759007
2006 Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway. Journal of virology 23 16873269
2006 Genetic environment of acquired bla(ACC-1) beta-lactamase gene in Enterobacteriaceae isolates. Antimicrobial agents and chemotherapy 23 16982793
1979 Studies on lung tumours. IV. Correlation between [3H]thymidine labelling of lung and liver cells and tumour formation in GRS/A and C3Hf/A male mice following administration of dimethylnitrosamine. Chemico-biological interactions 23 428013
2023 CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma. Blood 22 37562004
2020 LncRNA HORAS5 promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. Epigenomics 22 32618200
2022 Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. Translational oncology 21 35114569
2007 Overexpression of the antiapoptotic gene Bfl-1 in B cells from patients with familial systemic lupus erythematosus. Lupus 21 17402365
2015 Conditional knockdown of BCL2A1 reveals rate-limiting roles in BCR-dependent B-cell survival. Cell death and differentiation 19 26450454
2014 Up-regulation of cyclinD1 and Bcl2A1 by insulin is involved in osteoclast proliferation. Life sciences 19 25066930
2011 High-throughput fluorescence polarization assay for chemical library screening against anti-apoptotic Bcl-2 family member Bfl-1. Journal of biomolecular screening 19 22156224
2009 Molecular epidemiology and genetic environment of acquired bla ACC-1 in Salmonella enterica serotype Livingstone causing a large nosocomial outbreak in Tunisia. Microbial drug resistance (Larchmont, N.Y.) 19 19857134
2022 BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer. Scientific reports 18 35260587
2011 The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1. Molecular cancer 17 21843371
2020 Selective Covalent Targeting of Anti-apoptotic BFL-1 by a Sulfonium-Tethered Peptide. Chembiochem : a European journal of chemical biology 16 32790056
2020 Mechanisms dissection of the combination GRS derived from ShengMai preparations for the treatment of myocardial ischemia/reperfusion injury. Journal of ethnopharmacology 16 32946961
2020 KCNN4 induces multiple chemoresistance in breast cancer by regulating BCL2A1. American journal of cancer research 16 33163271
2012 µ-Calpain conversion of antiapoptotic Bfl-1 (BCL2A1) into a prodeath factor reveals two distinct alpha-helices inducing mitochondria-mediated apoptosis. PloS one 16 22745672
2002 Immobilization of alpha-amylase from Bacillus circulans GRS 313 on coconut fiber. Applied biochemistry and biotechnology 16 12396132
1998 Expression of Bfl-1 in normal and tumor tissues: Bfl-1 overexpression in cancer is attributable to its preferential expression in infiltrating inflammatory cells. Human pathology 16 9670830
2024 Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library Screen. ACS medicinal chemistry letters 15 38894895
2020 An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells. Cancers 15 32580291
2014 Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737. Journal of biomolecular screening 15 24809353
2014 Nutlin-3 induces BCL2A1 expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway. International journal of oncology 15 24867259
2011 Flavokawain B induces apoptosis of human oral adenoid cystic cancer ACC-2 cells via up-regulation of Bim and down-regulation of Bcl-2 expression. Canadian journal of physiology and pharmacology 15 22115332
2022 Last but not least: BFL-1 as an emerging target for anti-cancer therapies. Biochemical Society transactions 14 35900226
2018 Genetic risk score (GRS) constructed from polymorphisms in the PON1, IL-6, ITGB3, and ALDH2 genes is associated with the risk of coronary artery disease in Pakistani subjects. Lipids in health and disease 14 30261890
2018 BFL1 modulates apoptosis at the membrane level through a bifunctional and multimodal mechanism showing key differences with BCLXL. Cell death and differentiation 14 30560933
2013 BCL2A1 is a potential biomarker for postoperative seizure control in patients with low-grade gliomas. CNS neuroscience & therapeutics 14 23841872

Missed literature

Know a paper Affinage missed for BCL2A1? Flag it for the maintainers and the community.

No submissions yet.